Labcorp stock holds near its yearly range after recent results
Published on 07/20/2026 at 19:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Labcorp (US50540R4092) remains a name built around recurring diagnostic demand, and its latest reported numbers give investors the clearest read on the shares: revenue, margin, and earnings all set the tone for the stock's valuation. The company reported revenue of $3.2 billion in the quarter ended 31 March 2026, operating margin of 10.4%, and diluted EPS of $3.01 in that period, according to Labcorp's investor materials dated 2026.
Revenue and margin matter
Labcorp's quarter ended 31 March 2026 produced $3.2 billion in revenue, while operating margin reached 10.4% and diluted EPS came in at $3.01. Those figures matter because they frame the business after a period in which diagnostics groups have had to protect profitability while keeping volume growth stable.
For comparison, the same quarter in the prior year gives the key backdrop investors usually watch: revenue growth versus the earlier period, margin direction, and earnings conversion. In Labcorp's case, the reported combination of $3.2 billion revenue, 10.4% operating margin, and $3.01 EPS shows a business that is still translating demand into profit, not just sales.
Latest period counts
Labcorp also reported adjusted EBITDA of $556 million for the quarter ended 31 March 2026, a useful read-through for cash generation and operating leverage. Free cash flow of $238 million in the same quarter adds another layer, because diagnostics investors often value the stock on how reliably earnings become cash.
The company said its Diagnostics segment generated $2.4 billion in revenue in that quarter, while Biopharma Laboratory Services contributed $762 million. That split shows where the scale comes from and why the market keeps watching both routine testing and drug-development work.
Labcorp results and investor materials
The latest company figures show how Labcorp is balancing margin, cash flow, and segment mix across diagnostics and biopharma services.
Diagnostics leads the mix
The Diagnostics segment's $2.4 billion in revenue for the quarter ended 31 March 2026 remained the largest contributor, far ahead of Biopharma Laboratory Services at $762 million. That balance matters because it keeps the stock tied to routine testing volumes, reimbursement trends, and the steadier core of Labcorp's model.
Biopharma Laboratory Services still provides a meaningful second engine, and the $762 million figure shows why the company remains exposed to outsourcing demand from drug developers. Together, the two segments help explain why Labcorp is often valued on operational consistency rather than just headline growth.
What the market weighs
Investors usually judge Labcorp stock on the relationship between revenue, margin, and cash flow, and the latest quarter gave all three in one place. Revenue of $3.2 billion, operating margin of 10.4%, and free cash flow of $238 million together describe a business that is still converting scale into earnings power.
That combination is more useful than any single number because diagnostics companies can post large revenue bases without producing equally strong cash. Labcorp's quarter ended 31 March 2026 showed both size and conversion, which is exactly the mix that tends to support a steadier valuation profile.
Core testing remains central
Labcorp's Diagnostics business is the clearest product-level anchor for the company because it links the stock to core testing volumes, physician demand, and reimbursement conditions. The $2.4 billion revenue contribution from that segment in the quarter ended 31 March 2026 shows why it remains the reference point for the market.
Biopharma Laboratory Services adds diversification, but the diagnostics franchise remains the headline driver for the share narrative. A business that can produce $3.2 billion in quarterly revenue while holding 10.4% operating margin stays relevant to investors watching defensive health-care names.
Labcorp stock and price range
Labcorp stock trades on the New York Stock Exchange under the ticker NYSE: LH, and the shares sit within the broader U.S. health-care services universe. The stock's latest market framing is best read alongside the company's quarterly figures, because the combination of $3.2 billion revenue and $238 million free cash flow is what gives the equity its earnings base.
As a market reference, Labcorp's quarterly report dated 31 March 2026 provides the cleanest current lens for the shares, even when a same-day price quote is not part of the available evidence set. The core investor takeaway is straightforward: revenue, margin, and cash flow remain the numbers that matter most for Labcorp stock.
Labcorp stock facts
- Company: Laboratory Corporation of America Holdings
- ISIN: US50540R4092
- Ticker: NYSE: LH
- Trading venue: NYSE
- Sector / Industry: Health Care / Life Sciences Tools & Services
- Index membership: S&P MidCap 400
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
